Latest
Saturday, April 4, 2026
Growth Strategy for Biotech & Pharma Companies
Biotech companies raise capital on clinical promise but grow on commercial execution. The ones that scale build growth infrastructure alongside their pipeline — not after approval forces them to scramble.
Saturday, April 4, 2026
The Founder-Led Marketing Trap
Founder-led marketing is the most authentic, conversion-driving marketing a company can have. It's also the least scalable. When the founder is the brand, the content engine, and the sales closer, growth has a ceiling equal to the founder's time.
Friday, April 3, 2026
Go-to-Market Strategy for Biotech & Pharma Companies
Half of FDA-approved drugs underperform commercial projections in their first year. The difference between the winners and the rest isn't better science — it's better go-to-market strategy built years before launch day.
Friday, April 3, 2026
The End of Growth at All Costs
For a decade, the playbook was simple: raise capital, burn it on acquisition, show growth, raise more. That game is over. The companies winning now are the ones that grow efficiently — where every marketing dollar produces predictable, measurable return.
